Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials-Reference-Cited by-同舟云学术

Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials

Published:2022-08-28 Issue:11 Volume:38 Page:1909-1922
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Mease Philip¹,Kuritzky Louis²,Wright Wendy L.³,Mallick-Searle Theresa⁴^ORCID,Fountaine Robert⁵,Yang Ruoyong⁶,Sadrarhami Mojgan⁶,Faison Warachal⁶,Johnston Elizabeth⁷,Viktrup Lars⁷^ORCID

Affiliation:

1. Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA

2. University of Florida, Gainesville, FL, USA

3. Wright & Associates Family Healthcare, Amherst, NH, USA

4. Stanford Health Care, Redwood City, CA, USA

5. Pfizer Inc., Groton, CT, USA

6. Pfizer Inc., New York, NY, USA

7. Eli Lilly and Company, Indianapolis, IN, USA

Publisher

Informa UK Limited

Subject

General Medicine